Falling asleep faster is not enough. A medication can make the night easier while reducing alertness the next day. To compare options, the right framework combines the problem being treated, the planned duration, interactions and daytime functioning.
For chronic insomnia, cognitive behavioural therapy for insomnia, or CBT-I, remains the first-line treatment. A medication may have a defined role agreed with a healthcare professional, but no class deserves the title of “best sleeping pill” for all adults. Assurance maladie reiterates this priority and the limitations of hypnotics.
This document-based guide concerns adults and the French healthcare context. It is intended to help you prepare for a consultation, without personalised choices, doses to try or a discontinuation protocol. Checking the documentation does not replace an independent medical review, which still needs to be completed before the publication planned in the brief.
Occasional or chronic insomnia: assessment before medication
Difficulty sleeping after stress or travel raises different questions from months of disrupted nights. It is important to clarify whether you struggle to fall asleep, stay awake for long periods during the night or wake too early in the morning, despite having enough opportunity to sleep.
Chronic insomnia involves repeated difficulties, daytime impact and a duration of at least three months. This diagnostic benchmark is not an instruction to wait: disabling fatigue, drowsiness, concentration difficulties or distress are already reasons to discuss it. Assessment relies primarily on an interview and a sleep diary, according to the European guideline on insomnia.
The assessment looks in particular for sleep apnoea, restless legs, pain, a mood disorder, a shifted sleep schedule or a medication effect. Insomnia may also require treatment in its own right even when another condition is present. The guide to navigating sleep disorders · FR helps organise this information.
One example changes the whole discussion: “I wake up five times” does not tell us whether those awakenings follow choking episodes, hot flushes or prolonged worry. Increasing sedation does not address these three situations in the same way. The consultation needs to identify the target before choosing the drug.
What the different classes do
Benzodiazepines and related drugs such as zolpidem or zopiclone enhance the inhibitory action of GABA. Sedating antihistamines reduce a histamine-related wakefulness signal in the brain. Daridorexant blocks orexin receptors, which help maintain wakefulness. Melatonin acts on receptors involved in regulating the sleep–wake rhythm.
These mechanisms, described in the summaries of product characteristics (SmPCs) cited below, explain pharmacological differences. They cannot be used to rank treatments by sleep quality or safety. A receptor name is no substitute for a clinical result.
Table of indications, durations and risks
The durations below are limits or reassessment benchmarks drawn from specific documents. They are neither target durations nor permission to continue on your own. The properties of one drug do not automatically extend to its entire class.
| Class and example | Relevant situation in the French context | Duration or reassessment | Next-day alertness and limitations |
|---|---|---|---|
| Hypnotic benzodiazepine, example: lormetazepam | Severe, occasional or transient sleep disorders | Treatment as brief as possible, up to four weeks including tapering, according to the SmPC | Drowsiness, amnesia, falls, dependence and rebound. Not a long-term treatment for chronic insomnia |
| Related “Z-drugs”, zolpidem and zopiclone | Severe occasional or transient insomnia | Up to four weeks, including tapering, according to the SmPCs | Psychomotor impairment, dependence, complex sleep behaviours. Their different structure does not eliminate these risks |
| Sedating H1 antihistamine, doxylamine | Occasional insomnia in adults | Two to five days, not exceeding five days according to the SmPC | Residual drowsiness and anticholinergic effects. Not suitable for chronic use |
| Prolonged-release melatonin, reference medicinal product studied | Short-term treatment of primary insomnia characterised by poor sleep quality, from age 55 | Up to thirteen weeks according to its SmPC | May cause drowsiness. Narrow indication, not transferable to every melatonin supplement |
| Orexin receptor antagonist, daridorexant | Adults with insomnia lasting at least three months and a significant daytime impact | As brief as possible, with continued appropriateness reassessed within the first three months and periodically thereafter | Drowsiness, dizziness and interactions. Contraindicated in narcolepsy, among other conditions |
| Other sedating psychotropic drugs | Any potential role depends on the associated diagnosis and the drug’s marketing authorisation | No common schedule applies to the whole class | An antidepressant or antipsychotic does not become an ordinary sleeping pill just because it makes you drowsy |
Table sources: SmPCs for lormetazepam, zolpidem, zopiclone, doxylamine, prolonged-release melatonin and daridorexant. The role of other psychotropic drugs is discussed in the European guideline.
Three shortcuts to avoid
Available without a prescription does not mean safe. Doxylamine has contraindications, including certain types of glaucoma and urinary disorders with a risk of retention. Its SmPC also warns of possible worsening of existing sleep apnoea. The dedicated guide to antihistamines for sleep · FR covers this class without repeating its full review here.
“Melatonin” does not mean one interchangeable option. The formulation, indication and product status matter. The SmPC for the prolonged-release medicine does not validate all supplements or all uses in younger adults. For this distinction, see the guide to prolonged-release melatonin · FR.
“New class” does not mean “zero risk”. For daridorexant, the HAS concluded in 2023 that it had a second-line role and represented a minor improvement. Its assessment notes modest average effects compared with placebo and the absence of a comparison demonstrating superiority over non-drug therapies. The HAS opinion should be read alongside the updated SmPC, without turning an authorisation into a personal promise.
Drowsiness, interactions and at-risk populations
The next day is part of the treatment
I use the concept of the Toll here: the hidden cost of a solution. In this case, that cost may be reduced alertness after an apparently better night. Duration of action varies with the drug, age, liver and kidney function, other treatments and the time actually available for sleep.
The SmPCs give different benchmarks: at least eight hours between zolpidem and an activity requiring alertness, particular caution during the twelve hours after zopiclone, and around nine hours before driving for daridorexant. These intervals do not guarantee fitness to drive. Persistent drowsiness or dizziness means you must not drive and should seek advice.
If you drive early, work at height or operate machinery, tell the prescriber the exact time of that commitment. “I have to get up at six” is more useful than “I’m working tomorrow”. Do not add a dose during the night to make up for a disappointing night’s sleep: the SmPCs for zolpidem and daridorexant do not provide for this kind of catch-up dose.
Alcohol and stacking sedatives
Combining these drugs with alcohol can increase psychomotor impairment. With benzodiazepines and related drugs, combinations with opioids carry particular risks of sedation and respiratory depression that can be severe. This risk appears in the SmPCs, even when each medication has a valid indication on its own.
Have everything you take checked, including allergy products, certain painkillers, anti-anxiety medications, supplements and recreational substances. The pharmacist also needs to know about occasional treatments. Interactions do more than add to drowsiness: some alter how a drug is eliminated. For example, the daridorexant SmPC contraindicates strong CYP3A4 inhibitors.
Situations to flag before any decision
Tell the healthcare professional about:
- older age, a recent fall, confusion or memory problems
- snoring with breathing pauses, respiratory disease or significant drowsiness
- pregnancy, plans to become pregnant or breastfeeding
- liver or kidney disease, glaucoma or difficulty urinating
- a history of dependence, depression or another psychiatric disorder
- sleepwalking or unusual behaviour after taking a medication
The exact contraindications differ by product. This list helps prepare for checking the SmPC; it does not replace that check. For zolpidem, a history of complex sleep behaviour after taking it is one contraindication.
If someone becomes difficult to wake or breathes abnormally after taking a medication, call 15 or 112 in France. In the event of dangerous night-time behaviour, seek immediate medical advice before taking another dose. If you take a treatment regularly, do not abruptly stop it on your own: Assurance maladie recommends medical support. This guide does not provide a withdrawal schedule.
CBT-I: also treating what keeps insomnia going
CBT-I is a structured therapy: it addresses, among other things, the association between bed and wakefulness, time spent in bed and thoughts that perpetuate the struggle to sleep. It goes beyond lifestyle advice alone. Its delivery is tailored to the patient, in consultations or through an evaluated digital programme.
Assurance maladie and the European guideline place it before medication for chronic insomnia. If access is difficult, ask for a referral and a plan for the waiting period. A lack of local availability calls for a practical solution, not prescription renewals without a goal.
The guide to CBT-I and sleep effort · FR explores these mechanisms in greater depth. Do not devise severe sleep restriction on your own, particularly if your alertness is already impaired.
Evening factors can also be reviewed during the assessment. The guide to evening meals, caffeine, alcohol and reflux · FR complements this approach. Changing your dinner, however, is no substitute for indicated CBT-I or treatment of an identified cause.
Consultation worksheet: what to bring, what to ask
A page of facts makes the consultation more precise. You can use the HTML worksheet to fill in on paper or its printable PDF version.
Before the appointment, gather the following:
- when the difficulties began, their frequency, trouble falling asleep or awakenings, and daytime consequences
- bedtimes and wake-up times, naps and driving commitments
- a complete list of medications and products taken, with actual dose, timing and how long you have taken them
- observed benefits and troublesome effects, including those noticed by people around you
- snoring, breathing pauses, pain, mood and other symptoms
During the appointment, aim to get written answers to these questions:
- What problem are we trying to treat, and should another cause be investigated?
- How can I access CBT-I suited to my situation?
- If a medication is chosen, what concrete benefit do we expect, and how will we check it?
- Which interactions and contraindications apply to my medical history and current treatments?
- What should I do if I miss a dose, do not get enough sleep or have an adverse effect?
- When should treatment be reassessed, and who will organise stopping it if appropriate?
A useful goal covers the night and the day: for example, reducing periods of wakefulness without increasing morning drowsiness. Writing it down helps distinguish a real benefit from simply feeling more knocked out. You do not need to try several sedatives on your own to prepare for this discussion.
The Verdict
Main sources
Documents consulted on 17 October 2026. The SmPCs below relate to specific medicinal products, not approval of every product in the same class.
